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Abstract
Genetic variation at immunoglobulin (Ig) gene variable regions in B-cells is created through a multi-step process involving
deamination of cytosine bases by activation-induced cytidine deaminase (AID) and their subsequent mutagenic repair. To
protect the genome from dangerous, potentially oncogenic effects of off-target mutations, both AID activity and mutagenic
repair are targeted specifically to the Ig genes. However, the mechanisms of targeting are unknown and recent data have
highlighted the role of regulating mutagenic repair to limit the accumulation of somatic mutations resulting from the more
widely distributed AID-induced lesions to the Ig genes. Here we investigated the role of the DNA damage sensor poly-
(ADPribose)-polymerase-1 (PARP-1) in the repair of AID-induced DNA lesions. We show through sequencing of the
diversifying Ig genes in PARP-1
2/2 DT40 B-cells that PARP-1 deficiency results in a marked reduction in gene conversion
events and enhanced high-fidelity repair of AID-induced lesions at both Ig heavy and light chains. To further characterize
the role of PARP-1 in the mutagenic repair of AID-induced lesions, we performed functional analyses comparing the role of
engineered PARP-1 variants in high-fidelity repair of DNA damage induced by methyl methane sulfonate (MMS) and the
mutagenic repair of lesions at the Ig genes induced by AID. This revealed a requirement for the previously uncharacterized
BRCT domain of PARP-1 to reconstitute both gene conversion and a normal rate of somatic mutation at Ig genes, while
being dispensable for the high-fidelity base excision repair. From these data we conclude that the BRCT domain of PARP-1 is
required to initiate a significant proportion of the mutagenic repair specific to diversifying antibody genes. This role is
distinct from the known roles of PARP-1 in high-fidelity DNA repair, suggesting that the PARP-1 BRCT domain has a
specialized role in assembling mutagenic DNA repair complexes involved in antibody diversification.
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Introduction
The generation of high affinity antibodies through affinity
maturation in B cells relies on the introduction of mutations into
expressed immunoglobulin (Ig) gene alleles by somatic hypermuta-
tion (SHM) or gene conversion (GCV). These closely related
processes are mediated through introduction of a DNA lesion by
activation-induced cytidine deaminase (AID), followed by fixation
of a mutation at or nearby the damage site via a mutagenic, rather
than the usual conservative, DNA repair mechanism [1,2].
Mutations must be restricted to the Ig genes to protect the rest
of the genome from accumulating potentially dangerous muta-
tions, although this protection is far from perfect. Analysis of the
mechanisms that direct mutagenesis to Ig loci has revealed the
existence of multiple layers of regulation. One level of control is
temporal regulation of expression of AID to activated B-cells in
germinal centers, where cells with non-beneficial mutations can be
quickly eliminated [3]. Another level of control is targeting of
AID-mediated deamination to expressed Ig loci and, less
frequently, a subset of other expressed genes through an as yet
undefined transcription-dependent mechanism [4,5]. A third level
of control is the Ig-specific targeting of mutagenic repair. While
identical lesions at non-Ig loci are usually repaired by a high-
fidelity mechanism, at Ig loci, a mutagenic repair pathway
predominates, either through translesion synthesis by error-prone
polymerases or GCV [6].
While mutagenesis is necessary for high affinity antibody
production, mistargeting of either the AID-mediated deamination
events or the mutagenic repair of incidental mutations has been
linked to the generation of B-cell lymphomas and leukemias
through the introduction of mutations into tumor suppressors and
proto-oncogenes such as Bcl6, Myc, RhoH, Pim1, and Pax5 [7,8,9].
Recent data suggest that mistargeting of mutations occurs more
frequently than previously thought, highlighting the importance of
understanding how the processes that induce these mutations are
targeted to specific genetic loci [6,10,11]. However, insights into
the biochemistry through which either DNA lesions or mutagenic
repair are targeted have been difficult to achieve, and so far have
PLoS Biology | www.plosbiology.org 1 July 2010 | Volume 8 | Issue 7 | e1000428been limited to the definition of cis-acting DNA elements required
for active mutagenesis at Ig loci [12,13].
The enzyme PARP-1acts as a gatekeeper of DNArepair. It is one
of the first proteins to respond to DNA damage, where it binds and
recruits the appropriate DNA repair enzymes. There is a slower,
background level of repair in PARP-1 deficient cells, but DNA
repair is severely impaired and these cells are rendered hypersen-
sitive to DNA damaging agents such as methyl methane sulfonate
(MMS), N-Methyl-N9-Nitro-N-Nitrosoguanidine (MNNG), and
ionizing radiation [14,15,16,17]. In addition to a well-established
role in base excision repair (BER), there is evidence that suggests
that PARP-1 may also play a role in repairing double strand breaks,
although whether by homologous recombination (HR), non-
homologous end joining (NHEJ), or micro-homology mediated
end joining (MMEJ) is still the subject of lively debate [14,18,
19,20,21].
A potential clue to the mechanisms of mutation targeting has
been suggested by a recent report that the enzyme PARP-1 is
constitutively bound to a DNA sequence within the Bcl-6 gene
[22]—a locus which is frequently the subject of off-target mutations
inB-cells[9,23].This observationpromptedustoevaluatemutation
targeting to the Ig loci in a PARP-deficient variant of chicken DT40
B-cell line, in which Ig loci are constitutively mutated via GCV.
Remarkably, we observe a nearly complete loss of GCV at Ig loci in
PARP-deficient cells that is independent of the rate of AID-induced
DNA lesioning. Functional analysis of PARP-1 variants demon-
strated that PARP-1 is necessary for repair of AID-mediated DNA
lesions, and that the capacity of PARP-1 to support GCV requires
its BRCT domain which, to our knowledge, has no previously
characterized function.
Results
The recent observation that PARP-1 is constitutively bound at
the Bcl-6 locus, a gene which is frequently the subject of
mistargeted mutations in B-cells, prompted us to explore the role
of PARP-1 in targeting mutations to Ig loci. Mice and humans
have two PARP proteins that respond to DNA damage (PARP-1
and PARP-2) [20,24]; while the murine knockout of PARP-1 is
viable, the double knockout is embryonic lethal at day 8 [25],
hindering use of murine systems for study of PARP function. Even
so, a recent study of PARP-1
2/2 mice revealed defects in T-cell
dependent B-cell responses, decreased AID expression in activated
B cells, and defects in antibody production [26], although, as
previously reported, SHM and antibody production are not absent
altogether [27]. However chickens have only one PARP enzyme
that responds to DNA damage, allowing a complete PARP
2/2
phenotype to be achieved via targeted knockout of the gene
encoding PARP-1 in the chicken DT40 B-cell line [14].
Inactive PARP-1 Mutant Blocks Repair of AID-Induced
Lesions
PARP-1 is thought to be one of the first proteins to respond to
DNA strand breaks, where it binds and recruits the appropriate
DNA repair enzymes [14,18,19,20,21]. Consistent with this
model, PARP-1 deficient DT40 cells are rendered hypersensitive
to DNA damaging agents such as MMS, MNNG, and ionizing
radiation [14,15,16,17]. To further define the parameters of
PARP-1’s role in these repair processes, we evaluated the
sensitivity of PARP-1
2/2 DT40 cells to MMS exposure, and
assessed the capacity of human WT PARP-1 (hPARP), a DNA
binding mutant of hPARP-1 (dZF2), and two enzymatically
inactive variants of hPARP-1 (DBD-CAT and E988K) to restore
survival upon MMS challenge (Figure 1A and B).
As expected, hPARP expression fully restores MMS resistance
to the PARP-1
2/2 cells, while the PARP-1 mutant lacking a DNA
binding domain due to mutations in the cysteines critical for zinc
finger folding is similar in phenotype to the knockout. In contrast,
a catalytic inactive PARP-1 mutant that contains only the DNA
binding domain and the catalytic domain minus the WGR portion
exhibited poorer survival than the PARP-1
2/2 cells (Figure 1B).
As previously shown, this is likely due to the aggregation of
inactive PARP-1 molecules at the site of DNA damage which
could block access of DNA repair enzymes to the damaged site
and/or deplete free PARP-1 and prevent binding and recruitment
of repair enzymes to other sites of damage [28].
Surprisingly, we found that even after repeated attempts in
parallel with successful transfection of other PARP-1 variants, we
could not reconstitute PARP-1
2/2 cells with a full length, inactive
variant of PARP-1 (E988K), and thus we could not analyze the
phenotype of PARP-1
2/2 cells reconstituted with that variant. As
this variant had been successfully expressed in mouse embryonic
fibroblasts previously [28], we reasoned that a major difference
between the DT40 cell context and other cell lines is the presence
of constitutive AID expression and diversification of the Ig loci in
DT40s. We therefore attempted expression of PARP-1(E988K) in
both wild type and AID-deficient DT40 cells. Remarkably, we
were unable to grow out any resistant clones in wild type DT40
cells, but clones stably expressing E988K readily grew from the
parallel transfection of AID
2/2 DT40s, with the transfection
yielding dozens of transformants of which 15 were subjected to
further analysis to verify expression (Figure 1C shows a
representative clone). When we subsequently attempted to
reconstitute E988K, AID
2/2 DT40 clones with AID in the 4/
TO vector (Invitrogen) with zeocin selection, of the 4 clones which
eventually grew in the selective media, all had downregulated
expression of E988K PARP-1 to below our limits of detection (as
detected by Western blot, unpublished data). This dramatic
selection against clones that coexpress AID and E988K suggested
Author Summary
To produce a limitless diversity of antibodies within the
constraints of a finite genome, activated B cells introduce
random mutations into antibody genes through a process
of targeted DNA damage and subsequent mutagenic
repair. At the same time, the rest of the genome must be
protected from mutagenesis to prevent off-target muta-
tions which can lead to the development of lymphoma or
leukemia. How antibody genes are specifically targeted is
still largely unknown. A potential player in this process is
the DNA-damage-sensing enzyme PARP-1, which recruits
DNA repair enzymes to sites of damage. Using a chicken B
cell lymphoma cell line because it has only a single PARP
isoform and constitutively mutates its antibody genes, we
compared the types of mutations accumulated in PARP-
1
2/2 cells to wild type. We found that in cells lacking
PARP-1, the major pathway of mutagenic repair was
disrupted and fewer mutations than normal were intro-
duced into their antibody genes. To identify what might
be important for mutagenesis, we tested different factors
for their ability to rescue this mutagenic deficiency and
found a role for the BRCT (BRCA1 C-terminal) domain of
PARP-1, a consensus protein domain known to be involved
in directing protein-protein interactions. Our evidence
suggests that PARP-1 may be interacting with another
hypothetical protein via its BRCT domain that is required
for the mutagenic rather than faithful repair of DNA lesions
in the antibody genes.
PARP-1 Is Required for Ig Gene Conversion
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induced by AID.
PARP-1
2/2 Cells Are Deficient in GCV at IgL and IgH
The sensitivity of DT40s expressing AID to expression of
PARP-1 E988K suggested that PARP-1 has a requisite role in
repair of AID-induced lesions, either at mutating Ig loci or off-
target lesions genome-wide. To assess the function of PARP-1 at
mutating Ig loci, we sequenced the variable regions of the Ig light
and heavy chains in PARP-1
2/2 and WT cells. While mutations
still detectably accumulated within Ig genes, although at a
dramatically reduced rate, the PARP-1
2/2 cells had essentially
no discernible GCV events (p,.0001 at IgL and p=.0436 at IgH,
Figure 2A and B). To confirm that the observed defect in GCV
was due to the actions of PARP-1, we examined a cell line
reconstituted with human PARP-1 (hPARP) (Figure 2C) and
found that hPARP restored the GCV frequencies to wild type
levels or above at both IgL (p=.0001) and IgH (p=.0108)
(Figure 2A and B), suggesting that PARP-1 not only is required to
repair AID-mediated deaminations but also influences the
outcome of the resulting repair.
In this analysis, all mutations that matched chicken Ig
pseudogene sequences published in the NCBI public database
were counted as GCV events. This includes a subset of
‘‘ambiguous’’ mutations, which match the pseudogenes but occur
as a single nucleotide change such that we cannot exclude the
possibility that it arose as a point mutation. While the work of
Saberi et al. shows that these mutations are generally true GCV
Figure 1. Functional effects of expression of human PARP-1 variants on survival in response to MMS-induced DNA damage. (A)
Schematic of domains of human PARP-1 and variants. The functional domains of PARP-1 consist of a DNA binding domain (DBD), automodification
domain (AMD), BRCT protein interaction domain (BRCT), and WGR/catalytic domain (WGR/Cat). The DBD contains 3 zinc finger domains, which are
unusual in that they have specificity for DNA structure rather than sequence and recognize single strand breaks (SSBs) or double strand breaks (DSBs)
[39,40]. TheAMD contains the lysine residues that actas poly-ADP-ribose (PAR) acceptors [35]. The WGR/catalytic domain catalyzes PAR formationwhen
the DBD is bound to DNA, and PARylation of the AMD is thought to serve as a signal to recruit DNA repair enzymes such as XRCC1 as well as facilitates
the release of PARP-1 from the site of DNA damage [41]. The BRCT protein interaction domain is of unknown function, as it has been shown to be
dispensable forPARP-1’s DNArepairfunctionsin previous analyses [16]. hPARP: full length humanPARP-1;dZF2:C125Y andC128Y mutations to prevent
foldingofthesecond zincfingerdomain; DBDCat:DNAbindingdomainfusedtoa non-functional portionofthecatalytic domain. (B)MMSsurvival assay
comparing survival of the PARP-1 variants to MMS-induced DNA damage. Survival is measured by the ability to proliferate after 1 h of exposure to MMS
at the indicated concentration. The experiment was performed in triplicate; error bars represent SEM. *** PARP-1
2/2, dZF2, and hPARP p,.0001
comparedtoWT;PARP-1
2/2 p,.0003 comparedtohPARP;{ p,.0001 comparedtoWT,p=.021comparedtoPARP-1
2/2; betweenPARP-1
2/2 anddZF2
there is no significant difference. (C) Western blot showing levels of variant PARP-1 and AID expression with b actin as a loading control.
doi:10.1371/journal.pbio.1000428.g001
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not affecting our conclusions, we have also analyzed the data with
the ‘‘ambiguous’’ mutations excluded from the analysis or scored
as point mutations (Figure S2). In these additional analyses, the
difference in GCV frequencies between WT and PARP2/2 cells
at the IgL locus remains highly significant (p,.0001 and p=.0006,
respectively), although the number of mutations scored at the less
well defined IgH locus was not sufficient to reveal a significant
difference in these more conservative analyses (p=.1023 and
p=.1280, respectively). Subsequent restoration PARP-1 expres-
sion restores GCV at both IgL (p=.0002 and p=.0029) and IgH
(p=.0108 and p=.0108). The individual mutations observed at
IgL can be found in Figure S1 and a schematic of mutations
observed at IgH is shown in Figure S2E.
AID Overexpression Does Not Restore GCV to PARP-1
2/2
Cells
In the course of characterizing the GCV of PARP-1
2/2 cells,
we observed that the PARP-1
2/2 cell line and its hPARP
derivative express less AID than the WT DT40 cells, and that the
PARP-1
2/2 and hPARP lines had a lower overall mutation rate.
As low AID expression seemed likely to be the inadvertent result of
selection during derivation of the parental PARP-1
2/2 clone that
was subsequently carried over to the reconstituted hPARP cell
line, we investigated whether the reduction in AID expression and
corresponding overall mutation rate could be influencing the
proportion of GCV events. For this purpose, we used a retroviral
vector to overexpress gallus gallus AID in each cell line, and
matched AID expression as well as IgL transcript levels in selected
clones (Figure 3B and C), as the rate of target gene transcription
has also been shown to affect mutation rate [30,31,32]. Consistent
with previous reports, overexpressing AID does not significantly
increase the proportion of mutations which are GCV events [29]
and does not restore GCV to the PARP-1
2/2 cells, in spite of
increasing the AID expression to well above the original WT levels
(Figure 3A and D). Interestingly, overexpression of AID does not
significantly increase the mutation rate in the PARP-12/2 cells as
it does in hPARP, and may be revealing a dose-dependent effect of
PARP-1’s ability to mediate GCV repair of deamination events as
increasing AID expression results in a WT GCV phenotype
intermediate to PARP-1
2/2 and hPARP (Figure 3A). Further-
more, our ability to generate high stable expression of AID in
PARP-1
2/2 cells suggests that the reduced mutation rate in
PARP-1
2/2 cells relative to hPARP reconstituted cells cannot be
explained by loss of cells that sustain AID-mediated lesions, but
rather may reflect a reduced rate of mutagenic repair of AID-
mediated lesions.
Figure 2. PARP-1 is required for Ig gene conversion. Gene conversion frequencies (+/2 SEM) are indicated as a percentage of total mutations
at IgL (A) and IgH (B). n=total number of mutations analyzed for each cell line at each locus. (C) Western blot showing PARP-1 and AID expression
levels with b actin as a loading control.
doi:10.1371/journal.pbio.1000428.g002
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Not Rescue GCV in PARP-1 Knockouts
As an initial step towards defining the role of PARP-1 in repair
of AID-induced lesions, we investigated the influence of chromatin
accessibility on mutagenic repair at Ig loci. It has been proposed
that PARP-1 modifies histones at the site of DNA damage to open
chromatin and increase the accessibility of a damaged site to repair
enzymes [33]. To determine whether altered chromatin accessi-
Figure 3. AID overexpression does not restore GCV to PARP-1
2/2 cells. (A) Gene conversion frequencies (+/2 SEM) in cell lines
overexpressing ggAID. n=total number of mutations analyzed for each cell line. The total number of sequences analyzed was 169 WT, 137 PARP-1
2/
2, and 106 hPARP. (B) Western blot showing increase in AID expression upon transduction with ggAID retrovirus. (C) IgL transcript levels (mean +/2
SEM) are similar in cell lines which do and do not support GCV. * p,.05, ns=not significant compared to hPARP. (D) AID expression levels do not
directly influence GCV frequencies. Blue bars are AID expression levels (mean +/
2 SEM) before (dark blue) and after (light blue) transduction with
ggAID cDNA as measured by Western blot and quantified by LICOR Odessey infrared imaging, normalized to b actin. Brown bars are GCV frequencies
(mean +/2 SEM) before (dark brown) and after (light brown) transduction with ggAID cDNA as a percentage of total mutations observed for the
indicated cell lines. *** p,.0001, * p,.05, ns=not significant.
doi:10.1371/journal.pbio.1000428.g003
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2/2 cells, we
cultured PARP-1
2/2 cells in trichostatin A, a histone deacetylase
(HDAC) inhibitor, as this has previously been shown to increase
GCV rates, presumably via increasing accessibility of the
pseudogene repair templates to repair machinery [34]. While
the percent and length of GCV events in WT cells went up
dramatically, indicating that the treatment was effective
(Figure 4A), the PARP-1
2/2 cells are still unable to carry out
GCV (Figure 4B). Thus, the mechanism of PARP-1’s role in
promoting GCV at Ig loci is not through increasing chromatin
accessibility.
PARP-1 Does Not Promote HR Repair of DSBs
Ig GCV in DT40s proceeds through a pathway involving HR.
Since PARP-1 has previously been implicated in HR repair, we
assessed whether PARP-1’s capacity to promote Ig GCV was a
part of a general role for PARP-1 in promoting HR by evaluating
the capacity of PARP-1
2/2 cells to mediate HR in response to a
single DNA double strand break generated by the homing
endonuclease I-SceI (Figure 5A). In a single-copy, integrated
assay of HR, we find that the expression of PARP-1 does not
promote HR. Rather, in agreement with studies by Wang et al.,
PARP-1 may suppress HR and promote alternate DNA repair
pathways (Figure 5B) [19]. This result indicates that the activity of
PARP-1 at Ig loci is not part of a global role promoting HR, and
further supports the hypothesis that PARP-1 has a specific role
within GCV as a mutagenic repair pathway operating at Ig loci. It
also raises the question of whether it is best to consider GCV at Ig
loci as an unusual, mutagenic instance of otherwise high-fidelity
HR or if a better model would be to consider GCV one pathway
for mutagenic repair at Ig loci that uses much, but not all, of the
same repair machinery as HR.
Figure 4. Culture in TSA increases GCV rates at IgL in a PARP-1-dependent fashion. (A) Line drawing depicting point mutations (lollipops)
and gene conversion events (bars) at WT IgL in the absence and in the presence of TSA. (B) Proportion of total mutations that are GCVs in TSA treated
cultures. Error bars are (+/2) SEM. n=total number of mutations observed for each cell line.
doi:10.1371/journal.pbio.1000428.g004
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DNA Repair, Is Required for Ig GCV
To further investigate the mechanism by which PARP-1
mediates GCV, we evaluated the role of specific PARP-1
subdomains in promoting mutagenic repair at Ig loci. Hypothe-
sizing that the role of PARP-1 in mutagenic repair at Ig loci may
be distinct from its established role in high-fidelity BER, we
compared DNA BER and Ig GCV among PARP-1
2/2 clones
reconstituted with PARP-1 variants containing deletions or
inactivating mutations in each domain. Consistent with their lack
of ability to reconstitute any detectable DNA BER (see Figure 1),
sequence analysis of Ig loci in PARP-1
2/2 cells reconstituted with
the dZF2 or DBD-CAT variants indicated that expression of
either of these PARP-1 variants was unable to reconstitute Ig GCV
(Figure S3). We then analyzed PARP-1 variants that retained
significant capacity to reconstitute BER in the PARP-1
2/2 cells.
Analysis of PARP-1
2/2 cells reconstituted with variants of PARP-
1 containing either a deletion of the BRCT domain (dBRCT lacks
aa384–479) or the automodification domain sparing the BRCT
domain (dAMD lacks aa372–383 and 480–524) (Figure 6A) gave
surprising results. In an MMS survival assay, the dBRCT cells
survived as well as WT cells (Figure 6C), consistent with previous
data from our lab and others indicating that the BRCT portion of
the automodification domain is not required for PARP activation
via base-damaging agents or PARP-dependent base excision
repair [16,35]. In the same assay, dAMD-expressing cells
exhibited an intermediate survival phenotype when treated with
MMS (Figure 6C), consistent with the dAMD mutant exhibiting a
significant but delayed capacity to catalyze NAD degradation and
ADPR production in response to base damaging agents [16]. We
then assayed the ability of these cell lines to undergo GCV at IgL
and found that the capacity to mediate GCV does not correspond
with the ability of the cells to carry out global high-fidelity DNA
repair. In contrast, sequence analysis of Ig loci revealed that the
dBRCT cells, like PARP-1
2/2 cells, were essentially unable to
mediate GCV and had a correspondingly low overall mutation
rate, whereas the dAMD cells were able to gene convert at IgL at
or near WT levels (Figure 6D and Figure S3). This observation
demonstrates that the role of PARP-1 in mutagenic GCV at Ig loci
is distinct from its role in high-fidelity DNA BER. Furthermore, it
implies a novel role for the BRCT domain of PARP-1 in
mediating mutagenic DNA repair at Ig loci.
Independent of AID Expression, PARP-1
2/2, and dBRCT
Variants Accumulate Mutations at a Lower Rate than WT
or hPARP
When AID is overexpressed in cells overexpressing PARP-1
(hPARP), we observe that the mutation rate increases accordingly.
However, when AID is overexpressed in PARP-1
2/2 cells, we do
not see a significant change in mutation rate. This suggests that
Figure 5. PARP-1 does not promote HR in an integrated reporter assay. (A) Schematic of HR reporter assay. eBFP target containing I-SceI
target sequence is integrated into host genome. I-SceI and repair template are transfected into cells. HR repair of DSB is detected by GFP fluorescence
measured by flow cytometry. (B) Percent GFP positive cells normalized for transfection efficiency in indicated cell lines 48 h after transfection of I-SceI
and repair template. Data points represent independent experiments. There is no significant difference between WT and hPARP.
doi:10.1371/journal.pbio.1000428.g005
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PLoS Biology | www.plosbiology.org 7 July 2010 | Volume 8 | Issue 7 | e1000428Figure 6. The PARP-1 BRCT domain is required for immunoglobulin gene conversion. (A) Schematic of the domains of PARP-1 and
variants dAMD and dBRCT. (B) Western blot showing levels of PARP-1 and AID expression with b actin as a loading control. (C) Survival of PARP-1
variants to MMS-induced DNA damage. Experiment was performed in triplicate and error bars represent SEM. *** p,.0001 compared to WT or dBRCT;
{ p,.0001 compared to WT or dBRCT, p=.02 compared to dAMD. There is no significant difference between WT and dBRCT. (D) Frequencies of gene
conversion events as a proportion of total mutations at the IgL locus (+/2 SEM). n=total number of mutations analyzed for each cell line.
doi:10.1371/journal.pbio.1000428.g006
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GCV, expression of PARP-1may further limit mutation rate during
repair of these lesions (Figure 7A and B). One potential explanation
for these observations is that lack of PARP-1 selects against PARP-
1
2/2 cells with high AID expression that would have accumulated
mutations. To test this possibility, we evaluated the stability of AID
overexpression over the 3 wk culture period used for accumulation
of mutations, based on the rationale that selection pressure against
mutations would lead to a decreased expression of AID. In this
experiment, comparison of AID expression before and after 3 wk of
culture revealed no detectable difference in AID expression,
indicating that selection against the PARP-1
2/2 cells that would
have accumulated mutations cannot account for the observed
decrease in mutation rate in the PARP-1
2/2 cells (Figure 7C).
Thus, the observed lower mutation rate reflects either a decreased
rate of DNA lesioning or an increased rate of faithful repair of AID-
mediated DNA lesions. While the combined evidence of an
established role for PARP-1 in DNA repair and the baseline level
of mutations which continue to accumulate in the PARP-1
2/2 cells
lead us to prefer the latter hypothesis, we sought to resolve this issue
by expressing an UNG inhibitor UGI in the PARP-1
2/2 DT40
cells expressing endogenous levels of AID. UGI has been shown to
reveal an ‘‘AID footprint’’ of activity by blocking BER of
deaminated cytosines and increasing the relative frequency of
mismatch repair mutations at A/T and ‘‘replication over’’ events,
fixing C to T and G to A mutations at the site of deamination [36].
Correspondingly, we found that UGI expression results in
decreased transversion mutations at G/C base pairs, and a relative
increase in replication over errors at G/C and mismatch repair
mediated mutations at A/T base pairs (Figure 7E). Analyzing the
rate of mutation by sequence analysis, we observed that UGI
expressing PARP-1
2/2 cellsexhibitedan increased rate ofmutation
relative to their parent cell line, and now matched the mutation rate
observed in the hPARP cells (Figure 7D), chosen as a control
because they express a similar level of AID (see Figure 2). These
findings support our hypothesis that the low mutation rate of the
parentalcellline wasnottheresultofdecreased deamination events,
but rather reflected an increased proportion of high-fidelity repair.
This collection of evidence leads us to conclude that PARP-1 is
promoting mutagenic repair at Ig loci and that AID-induced lesions
are more likely to be repaired faithfully in the PARP-1
2/2 cells.
Discussion
In this paper, we studied the role of PARP-1 in mediating repair
of AID-induced lesions at diversifying Ig loci. By sequencing Ig
light and heavy chain genes in PARP-1
2/2 DT40 B-lymphocytes,
we found that the overall mutation rate is reduced and GCV is
essentially eliminated in the absence of PARP-1, and these defects
can be fully reconstituted by expression of the hPARP-1 gene.
Dissection of the biochemical mechanisms underlying PARP-1’s
involvement in Ig diversification demonstrated that PARP-1 DNA
binding and BRCT protein-protein interaction domain are
required, while the major site of automodification is not.
Furthermore, while the overall mutation rate in PARP-deficient
cells could be slightly increased by AID expression, restoration to
WT levels required concomitant inhibition of uracil-DNA-
glycosylase, suggesting that PARP-deficiency leads to an increased
rate of high-fidelity repair at Ig loci through the UNG-dependent
BER pathway. Taken together, our data suggest that PARP-1 is an
important part of the biochemical processes that promote
mutagenic repair over faithful repair at Ig loci, through a
mechanism that requires an intact BRCT domain.
The requirement for the BRCT domain of PARP-1 in promoting
mutagenic repairat Iglocirevealed inourstudies defines a novel role
for the BRCT domain of PARP-1. In spite of the extensive work
which has lead to our current understanding of the subdomains of
PARP-1, the function of the BRCT portion of the automodification
domain has remained a mystery, as it is not required for PARP-1
mediated repair of the other types of DNA damage which have been
studied [16,35]. As BRCT domains are thought to function as
protein-protein interaction domains, an intriguing possibility arising
from our observations is that there may be a protein interaction
partner of the PARP-1 BRCT domain which is involved in the
mutagenic repair of AID-induced lesions but not involved in high-
fidelity repair of other types of DNA damage. Identification of the
hypothetical interaction partner(s) for the PARP-1 BRCT domain
should further illuminate the mechanisms involved in PARP-1-
dependent targeting and regulation of mutagenic DNA repair.
PARP-1-dependent targeting of mutagenic repair may also account
forthefrequentmistargetingofmutationstotheBcl-6geneinB-cells,
as PARP is constitutively targeted to the Bcl-6 locus via sequence
specific binding of its zinc fingers [37], and it would be interesting to
see if PARP-1 also binds specifically to other common sites of
mistargeted mutations involved in malignant transformation such as
Bcl-2, Pim1, Pax5, Myc,o rRhoH.
Diverse lines of evidence have recently developed to support the
concept that AID-mediated DNA lesions are not uniquely targeted
to Ig loci [10,11] but rather that off-target deamination events in
germinal center B-cells went undetected because those that occur
outside the Ig loci primarily undergo high-fidelity repair [6]. This
new information emphasizes the importance of understanding not
just how AID is targeted to Ig loci but, equally as important, how
mutagenic repair of deaminations is targeted to the Ig loci to protect
B cells from the dangers associated with antibody diversification
such as oncogenesis. Our data demonstrating a role for PARP-1 in
both high-fidelity BER genomewide and mutagenic repair of
deaminations at Ig loci present a mechanism for the targeting of
mutagenic repair. PARP-1, known to play a key role in directing
repair of alkylated DNA bases towards BER through interactions
with the PARylated AMD, also directs repair down a mutagenic
pathway at Ig loci through interactions with the BRCT domain.
Our data suggest that in the WT system, PARP may be acting
at the site of a single strand break generated by AP lyase to either
(1) directly promote GCV repair of breaks that would otherwise
undergo high-fidelity repair or to (2) prevent high-fidelity repair at
Ig loci, resulting in diversion to the less efficient error-prone repair
pathways, including GCV and SHM (Figure 8). When normal
GCV pathways are blocked, such as in XRCC2/3 knockouts, the
lesions are diverted to other mutagenic repair pathways, such that
the total mutation rate is unchanged [38]. In PARP-1
2/2 cells, the
lesions enter a high-fidelity repair pathway rather than undergoing
GCV, which is more consistent with the latter hypothesis.
On the other hand, an early report from PARP-1
2/2 mice
would favor the former hypothesis, as the authors failed to find a
hypermutation defect in B cells from those mice [27]. However, in
those experiments Jacobs et al. examined ex vivo germinal center
B cells which had undergone intense selective pressure for the
accumulation of mutations. As we have shown that SHM is not
eliminated but reduced in the absence of PARP, and the reported
number of mutations in the PARP-1
2/2 mice was reduced by
more than one third (although they did not report how many
sequences were analyzed from each mouse), our results are not
in contradiction to this early report, and PARP-1 could still
play a role in inhibiting high-fidelity repair during SHM and
GCV. Additionally, a subsequent report identified reduced T cell-
dependent responses and reduced AID expression in PARP-1
2/2
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PLoS Biology | www.plosbiology.org 9 July 2010 | Volume 8 | Issue 7 | e1000428Figure 7. AID-induced lesions are more likely to undergo high-fidelity repair in PARP-1
2/2 cells. (A) Mutation rate is limited in PARP-1
2/2
cells, even when AID expression is restored. Blue bars show AID expression levels (mean +/2 SEM) before (dark blue) and after (light blue)
transduction with ggAID cDNA as measured by Western blot and quantified by LICOR Odessey infrared imaging, normalized to b actin. Yellow bars
show total mutation rates (mean +/2 SEM) before (dark yellow) and after (light yellow) transduction with ggAID cDNA, measured as total mutations/
bp/generation for the indicated cell lines. *** p,.0001, * p,.05, ns=not significant. (B) Increased AID expression restores mutation rate in hPARP to
WT levels, but PARP-1
2/2 remain reduced. (C) Western blot showing PARP-1, AID, and b-actin levels at the beginning and the end of the culture
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among hypermutating B cells consistent with the theory that
PARP-1
2/2 B cells accumulate fewer mutations than WT B cells,
and that the cells which fail to increase affinity by hypermutation
are selected against in germinal centers. Our results establish a role
for PARP-1 in the repair of the AID-induced lesions required for
SHM and GCV, and further show that this role is mediated in
part by the BRCT domain of PARP-1, a domain with, to our
knowledge, no previously known function. Without the BRCT
domain of PARP-1, the mutation rate is lower and GCV
essentially absent in DT40 B cells. The requirement for the
BRCT domain of PARP-1 may suggest that an interaction partner
for PARP-1 is important for mediating this role, likely by
inhibiting high-fidelity repair in the UNG-dependent BER
pathway and allowing alternative, mutagenic repair pathways to
predominate or, alternatively, by directly promoting GCV, thus
allowing fewer lesions to enter a high-fidelity repair pathway.
Materials and Methods
PCR and Sequencing of IgL and IgH
The variable regions of IgL and IgH were amplified with
Accuprime Pfx and blunt end Topo cloned. Single colonies were
picked and sequenced using the M13 reverse primer. The primers
used for PCR were IgL-F: CAGGAGCTCGCGGGGCCGT-
CACTGATTGCCG, IgL-R: GCGCAAGCTTCCCCAGCCT-
GCCGCCAAGTCCAAG, IgH-F: CGGGAGCTCCGTCAGCG-
CTCTCTGTCC, IgH-R: GGGGTACCCGGAGGAGACGATG-
ACTTCGG.
Categorization of Mutations
A baseline rate of mutation was determined by sequencing an
irrelevant gene, the constant region of IgL, or the variable region
of IgL in AID2/2 cells. The polymerases Pfx (Invitrogen) and Pfu
Ultra (Stratagene) were also compared (Figure S4). The baseline
mutation rates were well below the observed mutation rates in this
study, and we decide to proceed with our analyses using Pfx
Accuprime polymerase. Sequences were aligned using Phred and
Phrap and viewed in Consed. High quality base discrepancies
were noted and subjected to further analysis. As the total mutation
rate was much lower than 1 mutation/read, tracks of multiple
mutations in a read were scored as GCV events. Single mutations
for which no donor template could be identified were scored as
point mutations. To categorize ambiguous mutations (which
match the pseudogene templates but occur in isolation), results
were compared when these mutations were (1) excluded from the
analysis, (2) always considered point mutations, and (3) always
considered GCV events. These changes made little difference to
the final analysis as the mutations in the PARP-1
2/2 and dBRCT
cell lines very rarely matched the pseudogene sequences through
either blast searches or direct comparison to a database of
Figure 8. A model for the role of PARP-1 in GCV and SHM. PARP-1 increases GCV and decreases high-fidelity repair, although whether this is
accomplished by inhibiting high-fidelity repair and thus diverting repair to a mutagenic pathway or by directly promoting GCV is not yet clear.
doi:10.1371/journal.pbio.1000428.g008
period. (D) Mutation rate (mean +/2 SEM when available) in PARP-1
2/2 cells with and without UGI expression, compared to hPARP cells. (E) Tables
showing the distribution of mutations in PARP-1
2/2 and PARP-1
2/2UGI cell lines. The changes are scored from the nucleotide indicated on the left to
the nucleotide indicated on the top of the table.
doi:10.1371/journal.pbio.1000428.g007
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scored as point mutations. While the ability of WT DT40s to
undergo GCV is not in question, in order to avoid missing any
GCV events which may occur in the PARP
2/2 and dBRCT cell
lines, it was decided to use the most inclusive definition of a GCV
event, which is every mutation that matches the pseudogene
sequences (annotated as ‘‘similar to immunoglobulin lambda
chain’’ within gi 118098819) by blastn. At IgH, where the
pseudogenes are not well characterized, a match resulting from a
whole genome blast which was located adjacent to IgH was
considered a suitable donor sequence for a GCV event and again,
and all mutations with a donor template match were scored as
GCV events. In spite of the poor assembly at IgH, the availability
of donor templates as assessed is equivalent for all the cell lines
used, so they may be compared. p values were generated using
Fisher’s exact test.
RT-PCR and Quantification of IgL Transcript
Q-PCR was performed on a BioRad icycler using the BioRad
SYBR green master mix. The annealing temperature was 58uC.
The following primers were used: IgL-F: caggagctcgcggggccgt-
cactgattgccg, IgL-R: gcgcaagcttccccagcctgccgccaagtccaag, Beta
Actin F: tgagagggaaatcgtgcgtgacatc, Beta Actin R: caggaaa-
gagggttggaacagagcc. IgL transcript level was normalized to b-
actin and hPARP expression using the DDCt method. Data
analysis was performed using Microsoft Excel and Graphpad
Prism.
Western Blots
Whole cell lysates were separated by SDS-PAGE, transferred to
Millipore immobilon membrane, and probed with the following
antibodies: PARP-1: ALX-210-302 (Alexis Biochemicals), bActin:
A2228 (Sigma-Aldrich), and AID: LS-C34861 (Lifespan Biosci-
ences). Secondary antibodies were labeled with IRdye-700CW or
IRdye-800CW and analysis and quantification was done on the
LICOR Odyssey Infrared Imager.
Tissue Culture
DT40 cells were cultured in RPMI with 10% FBS, 5% CS,
Pen/Strep, and b-ME at 41u. PARP-1
2/2 cells and the WT
parent cell line were a generous gift from S. Takeda. Cell lines
reconstituted with hPARP-1 and the variant hPARP constructs
were generated by electroporation of PARP-1 cDNA in the 5/TO
vector (Invitrogen) at 550V, 25 uF in 4 mm cuvettes using the
GenePulser from Bio-Rad. Colonies which grew in hygromycin
were matched for PARP-1 expression by Western blot. AID
2/2
cells were a gift from JM Buerstedde. AID
2/2 cells transfected
with E988K were then transfected with human AID cDNA in the
4/TO vector (Invitrogen) as above, with selection in zeocin. Cells
treated with TSA were incubated in 2 ng/mL TSA (Sigma
T8552), refreshed daily, for the entire culture period. Cell lines
overexpressing AID used for mutation analysis were generated by
retroviral transduction of a plasmid encoding chicken AID IRES
GFP, another gift from S. Takeda. GFP high cells were subcloned
and AID expression was measured by Western blot. All cells used
for mutation analysis were subcloned by limiting dilution
immediately before the culture period to ensure a homogenous
starting population. Cells were then allowed to accumulate
mutations for a period of 6 wk in initial experiments and 4 wk
for experiments in which all the cell lines overexpress AID. There
were no notable differences in generation time and all cells were
split 1:16 every other day. For calculations which include
generation time, 12 h was used.
HR Assays
A recombination substrate encoding BFP containing an intron
with the recognition sequence for I-SceI was transduced into
DT40s using a limiting titer of lentivirus to bias toward single
integration events (cultures with less than 5% transduction
efficiencies were used). Transient transfection of a GFP repair
template plus I-SceI expression plasmid was performed by
electroporation at 250 V, 950 uF in 4 mm cuvettes. Parallel
transfection of a GFP control plasmid was used to estimate
transfection efficiency and frequency of HR was calculated as the
percent of mCherry positive cells that were also GFP positive,
divided by the percent that were positive for the GFP control.
MMS Survival Assays
Cells were exposed to MMS at the indicated concentrations for
1 h at 37u. They were then washed 26 in fresh media and
resuspended in 3 mL media. 450 ul of 3% agar was added and
1 mL was plated in triplicate. Plates were grown for 3–4 d at 41u
before colonies were counted.
Supporting Information
Figure S1 Mutations observed in the IgL sequence of
WT, PARP-1
2/2, and hPARP cell lines. Point mutations are
indicated below the reference sequence in red. Gene conversion
events are indicated in boxes. The total number of sequences
analyzed to generate these data were 93 WT, 184 PARP
2/2, and
186 hPARP, all after 35 d in culture (70 generations).
Found at: doi:10.1371/journal.pbio.1000428.s001 (0.24 MB PDF)
Figure S2 Different assessments of GCV do not change
the dependence on PARP-1. Gene conversion frequencies at
IgL when (A) percent gene conversion is calculated when
‘‘ambiguous’’ mutations (those that match upstream pseudogenes,
but occur in isolation) are excluded from analysis or (B) when
‘‘ambiguous’’ mutations are categorized as point mutations. (C)
and (D) are the same analyses at the IgH locus. (E) Line drawing
depicting point mutations (lollipops) and gene conversion events
(bars) in WT, PARP-1
2/2, and hPARP at the IgH locus.
Found at: doi:10.1371/journal.pbio.1000428.s002 (0.75 MB TIF)
Figure S3 Schematic representation of mutations ob-
served at IgL in multiple PARP-1 variants. Line drawing
depicting representative point mutations (lollipops) and gene
conversion events (bars) at IgL in each of the cell lines used in
this study after 30 d in culture (60 generations). (A) WT, 58 total
mutations in 168 reads. (B) PARP-1
2/2, 22 total mutations in 175
reads. (C) hPARP, 53 total mutations in 106 reads. (D) dAMD, 27
total mutations in 79 reads. (E) dBRCT, 16 total mutations in 236
reads. (F) DBDCat, 23 total mutations in 255 reads. (G) dZF2, 26
total mutations in 430 reads.
Found at: doi:10.1371/journal.pbio.1000428.s003 (0.56 MB TIF)
Figure S4 Background mutation rates of polymerase
and DT40s in culture. (A) Mutations accumulated in an
irrelevant gene in DT40 cells over 8 wk (120 generations) in
culture when amplified with Pfx (Invitrogen). (B) Mutations
accumulated in the constant region of IgL in DT40 cells over
6 wk (84 generations) in culture when amplified with Pfx
(Invitrogen). (C) Comparison of mutations accumulated in the
variable region of IgL in AID2/2 PARP
WT DT40 cells over
10 wk (140 generations) in culture when amplified with Pfx
(Invitrogen) or Pfu (Stratagene). (D) Comparison of mutations
accumulated in the variable region of IgL in Ugi expressing
PARP-1
2/2 DT40 cells over 3 wk (46 generations) in culture
when amplified with Pfx (Invitrogen) or Pfu (Stratagene).
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